A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects With Systemic Lupus Erythematosus With or Without Nephritis.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects With Systemic Lupus Erythematosus With or Without Nephritis.

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 18 Aug 2015

At a glance

  • Drugs Blisibimod (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Registrational; Therapeutic Use
  • Acronyms CHABLIS-SC2
  • Sponsors Anthera Pharmaceuticals
  • Most Recent Events

    • 12 Aug 2015 Planned primary completion date changed from 1 Aug 2016 to 1 Jun 2018 as per ClinicalTrials.gov record.
    • 12 Aug 2015 Planned initiation date changed from 1 Aug 2014 to 1 Dec 2015 as per ClinicalTrials.gov record.
    • 12 Aug 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top